Page 36 - Michael Erman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pfizer, which dominated COVID vaccine sales, now finds itself looking up at GSK, whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer. The British drugmaker's early advantage may be tied to its positioning as the lone RSV shot offered by CVS Health, the biggest pharmacy chain in the U.S. and a dominant player in the retail vaccine market, analysts and industry experts say. Price may also be playing a role, according to independent pharmacists.

Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs won't shrink their businesses.

Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs won't shrink their businesses....

Bristol Myers Squibb on Thursday pushed back by a year the time frame for its new-product portfolio to hit $10 billion in revenue as the sales ramp-up of medicines such as psoriasis treatment Sotyktu and multiple sclerosis drug Zeposia takes longer than initially projected.

(Reuters) -Merck & Co on Thursday reported higher-than-expected results in the third quarter on surprisingly strong demand for its COVID-19 treatment, primarily in Japan, and raised its annual sales forecast for the therapy. Sales of molnupiravir, the COVID-19 antiviral pill sold under brand name Lagevrio, jumped 47% to $640 million in the quarter, crushing Wall Street estimates of $120 million, according to LSEG data. Molnupiravir was initially hailed as a potential breakthrough when few treatment options were available, but was soon eclipsed by Pfizer's rival treatment Paxlovid, ...